FY2030 Earnings Estimate for RAPP Issued By HC Wainwright

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – Analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Rapport Therapeutics in a research report issued on Wednesday, March 11th. HC Wainwright analyst D. Tsao forecasts that the company will earn ($3.74) per share for the year. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($3.65) per share.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.07).

Other equities analysts have also recently issued reports about the company. TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a research report on Monday. Wells Fargo & Company raised their price target on Rapport Therapeutics from $43.00 to $46.00 and gave the company an “overweight” rating in a report on Wednesday. The Goldman Sachs Group reiterated a “buy” rating on shares of Rapport Therapeutics in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. Finally, Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.40.

Rapport Therapeutics Stock Performance

Rapport Therapeutics stock opened at $28.67 on Thursday. Rapport Therapeutics has a fifty-two week low of $7.73 and a fifty-two week high of $42.27. The stock has a market cap of $1.37 billion, a P/E ratio of -10.02 and a beta of 1.51. The firm’s fifty day moving average price is $28.11 and its 200-day moving average price is $26.90.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 5,833 shares of Rapport Therapeutics stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $29.34, for a total transaction of $171,140.22. Following the completion of the sale, the chief executive officer owned 556,247 shares of the company’s stock, valued at $16,320,286.98. The trade was a 1.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Bredt sold 8,500 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $29.02, for a total value of $246,670.00. Following the completion of the transaction, the insider owned 387,075 shares of the company’s stock, valued at $11,232,916.50. The trade was a 2.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 69,669 shares of company stock valued at $1,999,877 over the last quarter. 13.57% of the stock is owned by company insiders.

Hedge Funds Weigh In On Rapport Therapeutics

Large investors have recently modified their holdings of the company. Meeder Asset Management Inc. bought a new stake in Rapport Therapeutics in the 4th quarter worth approximately $37,000. Russell Investments Group Ltd. bought a new position in Rapport Therapeutics during the third quarter valued at approximately $43,000. Strs Ohio grew its position in Rapport Therapeutics by 23.5% during the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after acquiring an additional 400 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Rapport Therapeutics by 64.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock worth $70,000 after acquiring an additional 905 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Rapport Therapeutics by 86.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after acquiring an additional 4,582 shares in the last quarter.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.